Journal of Clinical Lipidology
Volume 4, Issue 4 , Pages 265-271 , July 2010

Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well-controlled low-density lipoprotein cholesterol levels

  • Erika M. Felix-Getzik, PharmD

      Affiliations

    • Division of Cardiology, Department of Medicine, Preventive Cardiology Center, Vascular Function Study Group, Tufts Medical Center, 800 Washington Street, Box 80, Boston, MA 02111, USA
    • Department of Pharmacy Practice, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA
    • ,
  • Jeffrey T. Kuvin, MD, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, Preventive Cardiology Center, Vascular Function Study Group, Tufts Medical Center, 800 Washington Street, Box 80, Boston, MA 02111, USA
    • ,
  • Richard H. Karas, MD, PhD

      Affiliations

    • Division of Cardiology, Department of Medicine, Preventive Cardiology Center, Vascular Function Study Group, Tufts Medical Center, 800 Washington Street, Box 80, Boston, MA 02111, USA
    • Corresponding Author InformationCorresponding Author.

Received 8 December 2009 ,Accepted 9 April 2010.

References 

  1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  2. Sacks Fm, Pfeffer MA, Moy LA, et al. The effects on pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  3. Miettinen TA, Gylling H, Strangberg T, Sarna S. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274–1275
  4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  5. Simes RJ, Marschner JC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial. Circulation. 2002;105:1162–1169
  6. Schwartz GC, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes-The MIRACL Study: a randomized controlled trial. JAMA. 2001;285:1711–1718
  7. Antman EM, Anbe DT, Kushner FG, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2004;44:671–719
  8. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2007;50:1–157
  9. Canon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (PROVE-IT). N Engl J Med. 2004;350:1495–1504
  10. Brown BG. Direct Comparison of the A to Z and PROVE IT Trials: A Second Chance to Gain a First Impression. Circulation. 2006;113:1382–1384
  11. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L–22L
  12. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8–15
  13. Olsson AG, Schwarts GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005;26:890–896
  14. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology Key Data Elements and Definitions for Measuring Clinical Management and Outcomes of Patients with Acute Coronary Syndromes. J Am Coll Cardiol. 2001;38:2114–2130
  15. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. Circulation. 2004;109:672–693
  16. American Diabetes Association. Standards of Medical Care in Diabetes–2008. Diabetes Care. 2008;31:S12–S54
  17. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systemic review. JAMA. 2007;298:786–798
  18. Robbins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA. 2001;285:1585–1591
  19. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine Website. Available at: https://nejm.org. Accessed March 25, 2010.
  20. Lopez-Sendon J, Mosca L, et al. Effects of torcetrapid in patient at high risk of coronary events. N Engl J Med. 2007;357:2109–2222
  21. Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes. AIM-HIGH Cholesterol Management Web site. Available at: http://www.aimhigh-heart.com/process.shtml. Updated unknown. Accessed August 20, 2009.
  22. HPS2-THRIVE: Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events. HPS2-THRIVE. Clinical Trials Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00461630. Accessed March 22, 2010.

PII: S1933-2874(10)00217-5

doi: 10.1016/j.jacl.2010.04.001

Journal of Clinical Lipidology
Volume 4, Issue 4 , Pages 265-271 , July 2010

Article Tools

* Image Usage & Resolution